Tango reported tumor shrinkage in 18 of 22 evaluable pancreatic cancer patients and plans a larger study. Side effects included dose-limiting problems at the higher dose, and another combination had a lower response rate, but the results support a positive read for Tango's treatment.
The response findings give Tango a reason to test the treatment in a larger study. The FDA discussions came before Tango's plan for a randomized trial in newly treated patients. The evidence is still early. Side effects limited the higher daraxonrasib dose, and another Tango combination had a lower response rate. The trial results support a positive read, but they do not yet show that the treatment will help patients broadly.
The results include tumor shrinkage among patients treated with Revolution Medicines' daraxonrasib in combination with Tango's drug. The patient groups were small and side effects occurred, so the findings are encouraging but do not yet prove the treatment helps patients broadly.
Follow Tango Therapeutics, Inc. (TNGX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TNGX